Physicochemical Properties
| Molecular Formula | C27H29NO10 |
| Molecular Weight | 527.52000 |
| Exact Mass | 527.179 |
| CAS # | 54110-25-7 |
| PubChem CID | 68711 |
| Appearance | Light yellow to yellow solid powder |
| Density | 1.244g/cm3 |
| Boiling Point | 594ºC at 760mmHg |
| Flash Point | 313ºC |
| Index of Refraction | 1.559 |
| LogP | 3.847 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 14 |
| Heavy Atom Count | 38 |
| Complexity | 653 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C(OCC1=CC=CC(COC(C2=CC(OC)=C(OC)C(OC)=C2)=O)=N1)C3=CC(OC)=C(OC)C(OC)=C3 |
| InChi Key | DIIBXMIIOQXTHW-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C27H29NO10/c1-31-20-10-16(11-21(32-2)24(20)35-5)26(29)37-14-18-8-7-9-19(28-18)15-38-27(30)17-12-22(33-3)25(36-6)23(13-17)34-4/h7-13H,14-15H2,1-6H3 |
| Chemical Name | [6-[(3,4,5-trimethoxybenzoyl)oxymethyl]pyridin-2-yl]methyl 3,4,5-trimethoxybenzoate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo |
One medicine that lowers cholesterol is pirozadil. Pirozadil has an effect on cerebral blood flow that is nearly identical to that of papaverine, less than that of nicardipine, and significantly higher than that of pyridinol carbamate and niacin, two other hypolipidemic/anti-atherosclerotic medications. Additionally, pirozadil has been demonstrated to considerably lower vascular cerebral resistance compared to niacin and pyridinol carbamate [1]. In anesthetized dogs, two doses of Pirozadil (1 mg/kg and 3 mg/kg) were administered intravenously. Cerebral blood flow (CBF) was measured at multiple time points before and after drug administration. After intravenous injection of 1 mg/kg Pirozadil, CBF started to increase at 10 minutes, reached a peak (25%-30% higher than the baseline value) at 30 minutes, and maintained this elevated level for approximately 60 minutes before gradually returning to baseline. For the 3 mg/kg dose group, CBF increased more significantly: it began to rise at 5 minutes, peaked at 15 minutes (40%-45% higher than baseline), and the elevated CBF persisted for about 90 minutes. During the entire experiment, there were no significant changes in arterial blood pressure or heart rate in the dogs of either dose group, indicating that Pirozadil could increase CBF in anesthetized dogs without affecting systemic hemodynamics [1] |
| Animal Protocol |
1. Animal selection and preparation: Healthy adult dogs (weighing 15-20 kg, both males and females) were used. Before the experiment, the dogs were fasted for 12 hours but allowed free access to water. Anesthesia was induced by intravenous injection of thiopental sodium (30 mg/kg) and maintained with 1.5%-2% halothane inhaled through an endotracheal tube. The dogs were placed in a supine position, and standard monitoring equipment was connected to record arterial blood pressure (via femoral artery catheterization) and heart rate [1] 2. Cerebral blood flow measurement: An electromagnetic flowmeter probe was surgically placed around the right common carotid artery (the main blood vessel supplying the brain) to continuously measure CBF. The probe was calibrated before the experiment to ensure accurate measurement. Baseline CBF, arterial blood pressure, and heart rate were recorded for 30 minutes to confirm stable physiological status [1] 3. Drug administration and data collection: Pirozadil was dissolved in physiological saline to prepare solutions corresponding to doses of 1 mg/kg and 3 mg/kg. The dogs were randomly divided into two groups (n=6 per group). Each group received the corresponding dose of Pirozadil via intravenous injection (injection time: 2 minutes). After administration, CBF, arterial blood pressure, and heart rate were recorded at 5, 10, 15, 30, 60, 90, and 120 minutes. At the end of the experiment, the dogs were euthanized humanely [1] |
| References | [1]. Roca J, et al. Effect of pirozadil on cerebral blood flow in anesthetized dogs. Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401. |
| Additional Infomation |
Pirozadil is a trihydroxybenzoic acid. Pirozadil is a nicotinic acid derivative with antilipidemic activity. Pirozadil exerts its effect of increasing cerebral blood flow possibly by dilating cerebral blood vessels, and its lack of significant impact on arterial blood pressure and heart rate suggests that it has a relatively selective effect on cerebral vascular beds rather than systemic blood vessels [1] |
Solubility Data
| Solubility (In Vitro) | DMSO : ~50 mg/mL (~94.78 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (3.94 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8957 mL | 9.4783 mL | 18.9566 mL | |
| 5 mM | 0.3791 mL | 1.8957 mL | 3.7913 mL | |
| 10 mM | 0.1896 mL | 0.9478 mL | 1.8957 mL |